Trial reportBreast cancer research and treatment2011
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
Trial report in Breast cancer research and treatment, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis.The Cochrane database of systematic reviews · 2024Pooled it
- Vitamin D Supplementation and Testosterone Levels in Breast Cancer Survivors.International journal of molecular sciences · 2025Trial
- The impact of an exercise program on quality of life in older breast cancer survivors undergoing aromatase inhibitor therapy: a randomized controlled trial.Health and quality of life outcomes · 2019Trial
- The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors.Obesity (Silver Spring, Md.) · 2017Trial
- Trial
- Impact + resistance training improves bone health and body composition in prematurely menopausal breast cancer survivors: a randomized controlled trial.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Trial
- Strength training stops bone loss and builds muscle in postmenopausal breast cancer survivors: a randomized, controlled trial.Breast cancer research and treatment · 2011Trial
- The association between adiposity and cardiac function in patients with early breast cancer receiving cardiotoxic therapies.Breast cancer research : BCR · 2026Article
- A Review on Testosterone: Estradiol Ratio-Does It Matter, How Do You Measure It, and Can You Optimize It?The world journal of men's health · 2025Review
- Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter?Breast (Edinburgh, Scotland) · 2024Observational
- Changes in body composition in early breast cancer patients treated with aromatase inhibitors.Journal of endocrinological investigation · 2024Observational
- Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting.Journal of clinical and translational hepatology · 2024Review
- Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer.Scientific reports · 2024Article
- Diabetes mellitus in breast cancer survivors: metabolic effects of endocrine therapy.Nature reviews. Endocrinology · 2024Review
- Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study.Endocrine connections · 2023Article
- Association between weight change and breast cancer prognosis.Breast cancer research and treatment · 2022Article
- Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.Circulation research · 2022Review
- Skeletal muscle wasting: the estrogen side of sexual dimorphism.American journal of physiology. Cell physiology · 2022Review
- Body composition and breast cancer risk and treatment: mechanisms and impact.Breast cancer research and treatment · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Aromatase inhibitors (AIs) have become the standard adjuvant therapy of postmenopausal breast cancer survivors. AIs induce a reduction of bioavailable estrogens by inhibiting aromatase, which would be expected to induce alterations in body composition, more extensive than induced by menopause. The objectives are to examine the impact of AIs on (1) DXA-scan derived body composition and (2) gonadal hormone levels. This is a sub-analysis of a 2-year double-blind, placebo-controlled, randomized trial of 82 women with nonmetastatic breast cancer, newly menopausal following chemotherapy, who were randomized to risedronate (35 mg once weekly) versus placebo, and stratified for their usage of AI versus no AI. Outcomes included DXA-scan derived body composition and gonadal hormone levels. As a group, total body mass increased in women over 24 months. Women on AIs gained a significant amount of lean body mass compared to baseline as well as to no-AI users (P < 0.05). Women not on an AI gained total body fat compared to baseline and AI users (P < 0.05). Free testosterone significantly increased and sex hormone binding globulin (SHBG) significantly decreased in women on AIs compared to no AIs at 24 months (P < 0.01) while total estradiol and testosterone levels remained stable. Independent of AI usage, chemotherapy-induced postmenopausal breast cancer patients demonstrated an increase of total body mass. AI users demonstrated maintenance of total body fat, an increase in lean body mass and free testosterone levels, and a decrease in SHBG levels compared to no-AI users. The mechanisms and implications of these changes need to be studied further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.